Stock Screener App

Frei -

Installieren

0.7679

2.94% 0.0219

Citius Oncology Inc (CTOR)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Citius Oncology Inc Aktie (CTOR) Neueste Nachrichten

Citius Oncology Announces Results of 2026 Annual Stockholder Meeting Votes - Kalkine Media

Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com Canada

Citius Pharmaceuticals at Moody Capital conference: launch gains traction By Investing.com - Investing.com UK

CTXR Stock Price, Quote & Chart - ChartMill

Citius Pharma CEO to speak at two New York conferences - Stock Titan

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences - PR Newswire

CITIUS ONCOLOGY, INC. SEC Filing (Aug 26, 2026) - Stock Titan

Citius (CTOR) Quarterly Results: The EPS Result Is Below Expectation in the Latest Session; Session Move: Shares Finish 2.02% Lower on the DayEPS Surprise History - vinanet.vn

Enterprise value to EBIT forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView

Armistice Capital Expands Citius Oncology (CTOR) Stake Despite Distress Signals - GuruFocus

Citius (CTOR) Quarterly Results: Reported EPS Misses Expectations in the Reported Period; After Results: The Market Price Advances 6.97% on the DayForward Guidance Trends - vinanet.vn

Citius Oncology Shares Slide 10% After Fiscal Q3 Revenue Misses Estimates Despite LYMPHIR Launch Gains - dars.gov.et

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum - Yahoo Finance

Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com Australia

Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com

Citius Oncology stock tumbles 10% on revenue miss despite launch progress - Investing.com

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination - The Clinical Trial Vanguard

CTOR Q2 2026 Earnings: Pre-Revenue Loss Misses Badly, Yet Shares Jump 10%EBITDA Analysis - vinanet.vn

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR) - simplywall.st

Citius Pharma Reports First LYMPHIR Revenue of $7.1M in Nine Months - minichart.com.sg

Citius Oncology Posts First Revenue from LYMPHIR Launch as Institutional Demand Surges 31% - Minichart

Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares - Stock Titan

Citius Pharma Q3 EPS beats estimate, sales miss by 72% - scanx.trade

Citius Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress - Intellectia AI

CTOR: LYMPHIR launch drove $7.1M revenue and 31% sequential vial order growth, with broad payer access - TradingView

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss - Stock Titan

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire

Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneInverse ETF Flow - vinanet.vn

Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake - Stock Titan

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - PR Newswire

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance

Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneRSI Oversold Picks - siam.in

Citius Oncology (CTOR) Advances 5.5% to $0.87 as Buyers Defend Support ZoneIsland Reversal - dars.gov.et

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake - Stock Titan

Citius Oncology appoints independent director Peri to board of directors - ROI-NJ

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia

People on the Move: Jonathan Peri, Ph.D., J.D., Joins Citius Oncology’s Board of Directors - BioBuzz

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - Morningstar

Citius Pharmaceuticals expands Citius Oncology board to nine with appointment of Jonathan Peri - Traders Union

Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com South Africa

Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Australia

Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Canada

Form 8K Citius Oncology Inc For: 12 August By Investing.com - Investing.com Nigeria

Citius Oncology adds independent director to expanded board - TipRanks

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Nigeria

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com India

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com - Investing.com Australia

Citius Oncology Adds Jonathan Peri to Board as LYMPHIR Commercialization Advances - citybiz

INCR

$4.57

1.72%

ZYBT

$1.40

6.67%

TLPH

$1.08

0.93%

CPIX

$7.18

4.77%

BGM

$8.65

0.70%

SCYX

$3.67

6.14%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters